Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5994194 | 0.95 | PPARA (0.50) | PPARAPPARGS1PR1S1PR2S1PR3 | |
| SCHEMBL10572189 | 0.83 | CALM1 (0.58) | CALM1ALDH1A1 | |
| SCHEMBL5991853 | 0.81 | FAAH (0.42) | PPARAPPARG | |
| SCHEMBL3655208 | 0.81 | CA2 (0.53) | PPARAPPARGALDH1A1KDM4EGAA | |
| SCHEMBL7040955 | 0.80 | S1PR1 (0.50) | S1PR1S1PR2S1PR3LTA4HALDH1A1 | |
| SCHEMBL7208039 | 0.80 | PPARA (0.45) | PPARAPPARGS1PR1S1PR3LTA4H | |
| SCHEMBL10181185 | 0.79 | CA2 (0.54) | PPARAPPARGALDH1A1KDM4EGAA | |
| SCHEMBL5542632 | 0.79 | PPARA (0.47) | PPARAPPARGCALM1MMP1MMP2 | |
| SCHEMBL5994202 | 0.79 | PPARA (0.49) | PPARAPPARGMMP1MMP2MMP7 | |
| SCHEMBL31497792 | 0.79 | MMP2 (0.41) | PPARAPPARGMMP1MMP2MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL | 2006-08-03 | — | — | US | disclosed |
| EP-1492764-B1 | PROCESS | ASTRAZENECA AB (SE) | 2006-06-28 | — | — | EP | disclosed |
| US-20060040979-A1 | 3-Aryl-2-hydroxypropionic acid derivative I | ANDERSSON KJELL | 2006-02-23 | — | — | US | disclosed |
| US-20050215808-A1 | New process | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| US-20050014955-A1 | Process for the preapartion 3-aryl-2-hydroxypropionic acid derivative | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | US | disclosed |
| EP-1492764-A2 | NEW PROCESS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL (SE) | 2004-11-18 | — | — | US | disclosed |
| US-20040229946-A1 | New 3-aryl-2-hydroxypropionic acid derivative I | ANDERSSON KJELL (SE) | 2004-11-18 | — | — | US | disclosed |
| EP-1237857-B1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| US-6750252-B2 | FOR USE IN CLINICAL CONDITIONS ASSOCIATED WITH INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2004-06-15 | — | — | US | disclosed |
| EP-1237856-A1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| EP-1237857-A1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| US-20010034371-A1 | New 3-aryl-2-hydroxypropionic acid derivative I | ANDERSSON KJELL (SE) | 2001-10-25 | — | — | US | disclosed |
| US-6258850-B1 | SULFONATE DERIVATIVES OF ETHER, ACIDS AS DRUGS | ASTRAZENECA AB (SE) | 2001-07-10 | — | — | US | disclosed |
| WO-2001040170-A1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040172-A1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| EP-1084103-A1 | NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE (I) | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062872-A1 | NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE (I) | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | PPARA 11/4885PPARG 22/4885S1PR1 2300/4885 |
| US-20010034371-A1 | New 3-aryl-2-hydroxypropionic acid derivative I | GPR119, IRS1, INSR | PPARA 79/4885PPARG 144/4885S1PR1 2644/4885 |
| US-20040229946-A1 | New 3-aryl-2-hydroxypropionic acid derivative I | GPR119, IRS1, INSR | PPARA 79/4885PPARG 144/4885S1PR1 2644/4885 |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | PPARA 11/4885PPARG 22/4885S1PR1 2300/4885 |
| US-20060040979-A1 | 3-Aryl-2-hydroxypropionic acid derivative I | GPR119, IRS1, INSR | PPARA 42/4885PPARG 95/4885S1PR1 2601/4885 |
| US-20050014955-A1 | Process for the preapartion 3-aryl-2-hydroxypropionic acid derivative | GRHPR, PAH, P4HA1 | PPARA 2485/4885PPARG 2770/4885S1PR1 1464/4885 |
| US-20050215808-A1 | New process | CFH, REN, CYP11B2 | PPARA 4075/4885PPARG 3890/4885S1PR1 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.